Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $23.4 million.

  • Compass Therapeutics' Net Cash Flow rose 3000.83% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 2736.57%. This contributed to the annual value of $19.3 million for FY2024, which is 27965.11% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Net Cash Flow is $23.4 million, which was up 3000.83% from -$18.2 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Net Cash Flow high stood at $23.4 million for Q3 2025, and its period low was -$18.2 million during Q2 2025.
  • Moreover, its 3-year median value for Net Cash Flow was -$2.4 million (2025), whereas its average is $1.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 19864.47% in 2024, then tumbled by 33953.07% in 2025.
  • Compass Therapeutics' Net Cash Flow (Quarter) stood at -$6.2 million in 2023, then soared by 198.64% to $6.1 million in 2024, then soared by 282.01% to $23.4 million in 2025.
  • Its last three reported values are $23.4 million in Q3 2025, -$18.2 million for Q2 2025, and -$2.4 million during Q1 2025.